E2 ModeratePreliminaryPEM requiredObservationalPeer-reviewedReviewed
Assessment and Incidence Determination of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following a SARS-CoV-2 Infection in a Prospective Cohort of Hospital Employees.
Tack, Matthias, Gruber, Rosalie, Betting, Leia et al. · Medicina (Kaunas, Lithuania) · 2026 · DOI
Quick Summary
This study followed hospital workers who got COVID-19 to see how many developed long-lasting fatigue and ME/CFS. About 12% still had fatigue months later, and 3% met the criteria for ME/CFS. Researchers found that people with these conditions often had signs of viral reactivation, immune system changes, and blood clotting abnormalities.
Why It Matters
This study provides concrete evidence that ME/CFS can develop after COVID-19 infection and identifies potential biological mechanisms—including viral reactivation and autoimmune activation—that might explain how post-viral infections trigger ME/CFS. Understanding these mechanisms is crucial for developing diagnostic tests and future treatments.
Observed Findings
- 11.8% of hospital employees with prior COVID-19 reported persistent fatigue 18+ months post-infection
- 3.2% met Canadian Consensus Criteria for ME/CFS diagnosis
- 66.6% of assessed individuals showed elevated autoantibodies against G-protein-coupled receptors
- 86.7% showed evidence of possible Epstein-Barr virus reactivation
- 42.1% demonstrated cognitive impairment on Montreal Cognitive Assessment
Inferred Conclusions
- Post-COVID-19 syndrome with ME/CFS is a measurable clinical outcome occurring in a subset of SARS-CoV-2-infected individuals
- Viral reactivation (particularly EBV), autoimmune activation, and coagulation cascade abnormalities may contribute to ME/CFS pathogenesis following COVID-19
- Multiple biological pathways appear simultaneously dysregulated in post-COVID ME/CFS, suggesting complex multifactorial disease mechanisms
Remaining Questions
- Why do only some COVID-19 patients develop ME/CFS while others recover fully, despite similar infection exposure?
- Are the identified biomarkers (EBV reactivation, GPCR autoantibodies, coagulation changes) causative or secondary consequences of ME/CFS?
What This Study Does Not Prove
This study does not prove that EBV reactivation, autoantibodies, or coagulation changes cause ME/CFS, only that they are associated with it in this small cohort. The lack of a control group means we cannot determine if these findings are specific to post-COVID ME/CFS or common in other populations. The findings cannot be generalized beyond hospital employees or establish causation.
Tags
Symptom:Post-Exertional MalaiseCognitive DysfunctionFatigue
Biomarker:AutoantibodiesBlood Biomarker
Phenotype:Infection-TriggeredLong COVID Overlap
Method Flag:Small SampleExploratory OnlyStrong PhenotypingNo Controls
Metadata
- DOI
- 10.3390/medicina62030480
- PMID
- 41901562
- Review status
- Editor reviewed
- Evidence level
- Single-study or moderate support from human research
- Last updated
- 12 April 2026
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Contribute
Private, reviewed by a human. Not a public comment thread.